S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
Log in
NASDAQ:CEMI

Chembio Diagnostics Stock Forecast, Price & News

$4.92
+0.11 (+2.29 %)
(As of 10/22/2020 02:22 PM ET)
Add
Compare
Today's Range
$4.76
Now: $4.92
$4.93
50-Day Range
$3.51
MA: $4.51
$5.44
52-Week Range
$2.25
Now: $4.92
$15.89
Volume31,785 shs
Average Volume2.51 million shs
Market Capitalization$99.19 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135
Employees295

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.46 million
Book Value$1.37 per share

Profitability

Net Income$-13,680,000.00

Miscellaneous

Market Cap$99.19 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$4.92
+0.11 (+2.29 %)
(As of 10/22/2020 02:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

How has Chembio Diagnostics' stock been impacted by COVID-19?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CEMI stock has increased by 58.7% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Chembio Diagnostics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Chembio Diagnostics
.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Chembio Diagnostics
.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.07. The company had revenue of $5.11 million for the quarter, compared to analysts' expectations of $4.60 million. Chembio Diagnostics had a negative return on equity of 72.75% and a negative net margin of 71.88%.
View Chembio Diagnostics' earnings history
.

What price target have analysts set for CEMI?

5 analysts have issued 1-year price targets for Chembio Diagnostics' shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate Chembio Diagnostics' share price to reach $6.50 in the next year. This suggests a possible upside of 32.1% from the stock's current price.
View analysts' price targets for Chembio Diagnostics
.

Are investors shorting Chembio Diagnostics?

Chembio Diagnostics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 4,290,000 shares, a decline of 10.3% from the August 31st total of 4,780,000 shares. Based on an average trading volume of 5,220,000 shares, the days-to-cover ratio is currently 0.8 days.
View Chembio Diagnostics' Short Interest
.

Who are some of Chembio Diagnostics' key competitors?

What other stocks do shareholders of Chembio Diagnostics own?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
  • Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
  • Mr. David A. Gyorke, Sr. VP & COO (Age 59)

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cadence Capital Management LLC (0.20%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, John Gary Potthoff and Robert Passas.
View institutional ownership trends for Chembio Diagnostics
.

Which major investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC.
View insider buying and selling activity for Chembio Diagnostics
.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $4.92.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $99.19 million and generates $34.46 million in revenue each year. The company earns $-13,680,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Chembio Diagnostics employs 295 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is www.chembio.com.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.